Table 2. Eligibility criteria–antithrombotic therapies.
| Drug Class | Medication |
|
|---|---|---|
| Anticoagulants | Vitamin K Antagonists | Warfarin |
| Acenocouramol | ||
| Phenprocoumon | ||
| Fluindione | ||
| Direct Factor Xa Inhibitors (FXaI) |
Apixaban | |
| Betrixaban | ||
| Edoxaban | ||
| Rivaroxaban | ||
| Direct Thrombin Inhibitors (DTI) |
Dabigatran | |
| Melagatran/Ximelagatran | ||
| Argatroban | ||
| Bivalirudin | ||
| Unfractionated Heparin (UFH) | ||
| Low Molecular Weight Heparins (LMWH) |
Dalteparin | |
| Enoxaparin | ||
| Nadroparin | ||
| Semuloparin | ||
| Tinzaparin | ||
| Indirect Factor Xa Inhibitors | Fondaparinux | |
| Heparinoids | Danaparoid | |
| Factor XIa Inhibitors | IONIS-FXIRX | |
| Osocimab | ||
| Abelacimab | ||
| Milvexian | ||
| Xisomab 3G3 | ||
| Fesomersen | ||
| Asundexian | ||
| Antiplatelet Agents | Non-steroidal anti-inflammatory drug (NSAID) |
Acetylsalicylic acid (ASA)/ Aspirin |
| P2Y12 Inhibitors | Clopidogrel | |
| Prasugrel | ||
| Ticagrelor | ||
| Ticlopidine | ||
| Cangrelor | ||
| GPIIb/IIIa receptor antagonists | Abciximab | |
| cAMP phosphodiesterase inhibitors | Dipyridamole | |